[Therapy of migraine. Clinical experience with Migraeflux, a new migraine drug].
The new migraine preparation Migraeflux has been subjected to clinical trial in a double-blind cross-over study in 32 single tests. Compared with other products, the 2-phase-preparation Migraeflux is distinguished--due to its antihistaminic ingredient--by the capacity of preventing in 2/3 of the cases the formation of a migraine attack if applied soon during the prodromal phase. If the attack is not prevented, the intensity of pain is lessened in 70% of the remaining cases and the duration of attack is markedly reduced. The preparation proved to be tolerated very well.
D000082:Acetaminophen / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D003061:Codeine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D004111:Dimenhydrinate / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008881:Migraine Disorders / Q000188:drug therapy* / Q000517:prevention & control; D013997:Time Factors
D004338:Drug Combinations; D000082:Acetaminophen; D004111:Dimenhydrinate; D003061:Codeine
Therapie der Migräne Klinische Erfahrungen mit Migraeflux, einem neuen Migräne-Präparat